An interventional study of Test Dentifrice and Reference Dentifrice in Dental Caries, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by HALEON · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Dental Caries with a site in United States — 16 open to participants now, 19 under way, 3 of them phase 3. Dental Caries · United States.
Among the 193 studies in Dental Caries with a site in United States, this one is the 105th largest by enrollment of the 168 interventional ones that give a count, is one of 8 that started in 2025, is one of 110 with no phase, and was the 179th registered.
1,174 studies on the registry are indexed under Dental Caries; 209 are open to participants now.
Browse Dental Caries studies →16 of the 193 studies in Dental Caries with a site in United States are open now. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 8–12
University of Michigan · Sites in United States
Ages 18–99
A.T. Still University of Health Sciences · Sites in United States
Ages 6–10
University of Pennsylvania · Sites in United States
Ages 5–13 · Healthy volunteers
University of Massachusetts, Worcester · Sites in United States
Ages 12 mo–45 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 19 · Phase 3 23 · Phase 4 4
First in 1996; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 60 across 967 interventional studies indexed under Dental Caries.
Median enrollment 60 across the 168 interventional studies, 264 across the 25 observational. Of the 166 that completed or were terminated, 68 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 193 have an industry lead sponsor. The 10 most frequent:
HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
HALEON has 1 study filed under Dental Caries — fewer than ten, so there is no comparison to draw.
6 of the studies in Dental Caries with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07124533Phase 3Loma Linda UniversityEffectiveness of Toothpaste Tablets on Plaque, Gingival Health and Caries Experiences | 2026-12 |
| NCT06588725Vanderbilt University Medical CenterBrief Interventions to Improve Behavior Outcomes and Prevent Cavities | 2027-01 |
| NCT05756413University of IowaBirth to Three - Cavity Free | 2027-03-31 |
| NCT07648212University of MichiganArtificial Intelligence (AI) for Proximal Caries Detection and Its Impact on Treatment Threshold | 2027-05 |
| NCT06714929Virginia Commonwealth UniversityAdvancing Water Security: A Community Participatory School-Based Hydration Intervention | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 193 studies in Dental Caries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the relative efficacy of an experimental dentifrice containing 1150 parts per million (ppm) fluoride (as sodium fluoride [NaF]) to remineralize early stage caries type lesions in an in situ model compared to a negative control and a reference dentifrice.
This is a randomized, single-blind, single-center, controlled, three period, three treatment, cross-over caries in situ model in healthy participants who wear a suitable removable mandibular partial denture. The denture will be modified to accommodate 2 gauze-covered, 4 millimeter (mm) round specimens of bovine dental enamel that have been previously demineralized in vitro to form artificial caries lesions. After 14 days of twice daily product use off-site, the specimens will be removed at the study site to determine the remineralization ability of the treatments. The same procedure will be followed for period 2 and 3 with a washout period of 2-3 days prior to each treatment period. Sufficient participants will be screened to randomize up to 50 participants to the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant with a removable partial denture (RPD) fulfilling:
Exclusion Criteria:
Participant who is:
Participant who has:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be instructed to dose the toothbrush provided with a strip of test dentifrice (a full brush head) and brush for one timed minute, twice daily (morning and evening) per the Brushing Instructions for up to 14 days each in Treatment Periods 1 to 3 as per crossover assignment. There will be a washout period of 2-3 days prior to each treatment period during which the participants will brush their teeth with the washout dentifrice for one timed minute, twice daily (morning and evening) per the Brushing Instructions.
Drug: Test Dentifrice
Participants will be instructed to dose the toothbrush provided with a strip of reference dentifrice (a full brush head) and brush for one timed minute, twice daily (morning and evening) per the Brushing Instructions for up to 14 days each in Treatment Periods 1 to 3 as per crossover assignment. There will be a washout period of 2-3 days prior to each treatment period during which the participants will brush their teeth with the washout dentifrice for one timed minute, twice daily (morning and evening) per the Brushing Instructions.
Drug: Reference Dentifrice
Participants will be instructed to dose the toothbrush provided with a strip of negative control dentifrice (a full brush head) and brush for one timed minute, twice daily (morning and evening) per the Brushing Instructions for up to 14 days each in Treatment Periods 1 to 3 as per crossover assignment. There will be a washout period of 2-3 days prior to each treatment period during which the participants will brush their teeth with the washout dentifrice for one timed minute, twice daily (morning and evening) per the Brushing Instructions.
Drug: Negative Control Dentifrice
Dentifrice containing 5 percent (%) weight by weight (w/w) Potassium nitrate (KNO3) and 1150ppm fluoride as sodium fluoride.
Dentifrice containing 1100ppm fluoride as stannous fluoride.
Dentifrice containing 5% KNO3 with no fluoride.
Percent Surface Microhardness Recovery (%SMHr) After 2 Weeks in situ (Experimental Dentifrice Versus [Vs] Negative Control Dentifrice)
The Surface Microhardness (SMH) technique is used to detect changes in the mineral content of dental enamel. The %SMHr will be derived as \[(D1-R)/(D1-B)\]\*100, where D1= mean of replicate indentation lengths (micrometer \[μm\]) in enamel after first in vitro demineralization, R= mean of replicate indentation lengths (μm) in enamel after 2-weeks in situ and B= mean of replicate indentation lengths (μm) in sound enamel at baseline.
Time frame: After 2 Weeks in situ in each Treatment Period
%SMHr After 2 Weeks in situ (Experimental Dentifrice Vs Reference Dentifrice)
The SMH technique is used to detect changes in the mineral content of dental enamel. The %SMHr will be derived as \[(D1-R)/(D1-B)\]\*100, where D1= mean of replicate indentation lengths (μm) in enamel after first in vitro demineralization, R= mean of replicate indentation lengths (μm) in enamel after 2-weeks in situ and B= mean of replicate indentation lengths (μm) in sound enamel at baseline.
Time frame: After 2 Weeks in situ in each Treatment Period
%SMHr After 2 Weeks in situ (Reference Dentifrice Vs Negative Control Dentifrice)
The SMH technique is used to detect changes in the mineral content of dental enamel. The %SMHr will be derived as \[(D1-R)/(D1-B)\]\*100, where D1= mean of replicate indentation lengths (μm) in enamel after first in vitro demineralization, R= mean of replicate indentation lengths (μm) in enamel after 2-weeks in situ and B= mean of replicate indentation lengths (μm) in sound enamel at baseline.
Time frame: After 2 Weeks in situ in each Treatment Period
Transverse Microradiography (TMR) Parameter - Integrated Mineral Loss (∆Z) After 2 Weeks in situ
Integrated Mineral Loss will be determined using TMR. TMR measures changes in mineral content by cutting the enamel specimens into plano-parallel thin slices and taking digitized microradiographic images of each. The mineral content is calculated from the gray intensity levels of the images of section.
Time frame: After 2 Weeks in situ in each Treatment Period
TMR Parameter - Lesion Depth (L) After 2 Weeks in situ
Lesion depth will be determined using TMR. TMR measures changes in mineral content by cutting the enamel specimens into plano-parallel thin slices and taking digitized microradiographic images of each. The mineral content is calculated from the gray intensity levels of the images of section.
Time frame: After 2 Weeks in situ in each Treatment Period
TMR Parameter - Maximum Mineral Density at the Surface Zone (SZmax) After 2 Weeks in situ
Maximum mineral density at the surface zone will be determined using TMR. TMR measures changes in mineral content by cutting the enamel specimens into plano-parallel thin slices and taking digitized microradiographic images of each. The mineral content is calculated from the gray intensity levels of the images of section.
Time frame: After 2 Weeks in situ in each Treatment Period
Enamel Fluoride Uptake (EFU) After 2 Weeks in situ
EFU gives valuable information regarding how much fluoride is incorporated into a remineralized lesion. In this technique the enamel is sampled through use of a microdrill to obtain a quantity of powdered enamel representative of the cross section through the lesion. The powder is dissolved in acid and chemically analyzed for fluoride.
Time frame: After 2 Weeks in situ in each Treatment Period
Percent Net Acid Resistance (%NAR) After 2 Weeks in situ and Further in vitro Demineralization
The resistance to acid-induced demineralization will be assessed through NAR. The %NAR (at the specimen level) will be derived as \[(D1-D2)/(D1-B)\]\*100, where D1= mean of replicate indentation lengths (μm) in enamel after first in vitro demineralization, D2= mean of replicate indentation lengths (μm) in enamel after the second in vitro demineralization and B= mean of replicate indentation lengths (μm) in sound enamel at baseline.
Time frame: After 2 Weeks in situ in each Treatment Period
Acid Resistance Ratio (ARR) After 2 Weeks in situ and Further in vitro Demineralization
The resistance to acid-induced demineralization will be assessed through ARR. The ARR will be derived as 1-\[(D2-R)/(D1-B)\] where, D2= mean of replicate indentation lengths (μm) in enamel after the second in vitro demineralization, R= mean of replicate indentation lengths (μm) in enamel after 2-weeks in situ, D1= mean of replicate indentation lengths (μm) in enamel after first in vitro demineralization and B= mean of replicate indentation lengths (μm) in sound enamel at baseline.
Time frame: After 2 Weeks in situ in each Treatment Period
Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Sep 2025, 4 months.
Of 33 industry-sponsored interventional studies with no phase under Dental Caries, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 4 months is below that.
Counting every sponsor, half of 502 studies reached it within 15 months; a quarter within 7 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.